A pricing benchmark that the industry itself nicknamed “Ain’t What’s Paid” would seem unlikely to survive the reputational damage. Average Wholesale Price has survived fraud lawsuits, congressional hearings, regulatory investigations, academic debunkings, and the emergence of multiple alternatives that more accurately reflect actual drug costs. It persists not because anyone defends its accuracy — no one does — but because dismantling it would require renegotiating the contractual infrastructure of the American pharmacy benefit.
AWP was originally intended to approximate the average price that wholesalers charged pharmacies for prescription drugs. That intention was reasonable in an era when the pharmaceutical supply chain was simpler and the relationship between published prices and actual prices was closer. Over time, the gap widened until the “average wholesale price” bore no empirical relationship to the average price wholesalers charged for anything. AWP became a derived number — typically WAC plus twenty percent for branded drugs — set by pricing compendia based on manufacturer-reported data. The markup was a convention, not a measurement. Nobody surveyed wholesalers. Nobody verified the number against invoices. AWP was manufactured, not measured.
The litigation that followed was substantial. Multiple states and the federal government brought suits alleging that pharmaceutical manufacturers inflated AWP to create artificial spreads that incentivized prescribing and generated phantom profits for providers. The legal theory was straightforward: by reporting inflated AWPs while offering drugs to providers at significant discounts below AWP, manufacturers created a gap — the “spread” — that functioned as a hidden incentive. Providers who bought at deep discounts and were reimbursed at AWP-based rates profited from the difference. Manufacturers who inflated AWP attracted prescribing volume from providers seeking to maximize spread. The arrangement was mutually beneficial and, courts found in several cases, fraudulent in its misrepresentation of actual market prices.
Despite the litigation, AWP did not disappear. It receded from some sectors — notably Medicaid, where CMS shifted to AMP-based rebate calculations and increasingly to NADAC
for reimbursement benchmarking — but remained embedded in commercial pharmacy contracts. PBM contracts with plan sponsors, pharmacy network agreements, and even some commercial payer reimbursement formulas continue to reference AWP as the base from which discounts are calculated. AWP minus seventeen percent. AWP minus twenty-one percent. The discount sounds aggressive. The base is inflated.
The persistence is structural, not conspiratorial. Renegotiating every pharmacy contract that references AWP to a different benchmark — NADAC, WAC, or some other alternative — would require alignment among PBMs, pharmacies, plan sponsors, and payers on a replacement standard, a transition timeline, and a set of new reimbursement formulas that preserve economically viable pharmacy margins. Each of these steps is contentious. Pharmacies that currently earn margin on the spread between AWP-based reimbursement and actual acquisition cost would see that margin compress under NADAC-based reimbursement unless dispensing fees were increased to compensate. PBMs that negotiate spread-based compensation — retaining the difference between what they charge plan sponsors and what they pay pharmacies — would face transparency pressure if the benchmark itself became more transparent. Plan sponsors might pay less in aggregate but would need to restructure dispensing fee arrangements to keep pharmacy networks viable.
The transition is happening, slowly. Several large commercial payers have shifted to NADAC or cost-plus reimbursement models. Some state employee health plans have adopted pass-through PBM arrangements that use NADAC or actual acquisition cost as the reimbursement base. The trend is toward empirical benchmarks and away from AWP. But the trend is gradual, uneven, and contested at every step by stakeholders who benefit from the status quo.
AWP’s survival carries a broader lesson about pharmaceutical pricing infrastructure. Once a benchmark is embedded in millions of contracts, its accuracy matters less than its ubiquity. Replacing an inaccurate but universal standard with an accurate but disruptive one requires not just a better number but a collective willingness to absorb the transitional costs of switching. The pharmaceutical market has demonstrated, repeatedly, that it prefers a known fiction to an uncertain truth — not out of ignorance, but out of institutional inertia reinforced by financial self-interest.
The irony is that AWP’s inflation is precisely what made it useful as a contracting base. A high benchmark allows for large discounts, which allow PBMs to demonstrate value to plan sponsors, which allows plan sponsors to report pharmacy savings, which allows the system to present itself as cost-conscious while preserving margins at every level. The discount is real. The savings are real in a nominal sense. But the baseline from which they are measured was never real.
Whether AWP will eventually disappear or merely continue to recede is difficult to predict. The forces pushing toward its replacement — regulatory pressure, competitive dynamics among PBMs, growing adoption of NADAC, and increasing client sophistication — are persistent but not decisive. The forces preserving it — contractual inertia, the cost of renegotiation, and the reluctance of beneficiaries to dismantle a profitable arrangement — are equally durable. AWP may ultimately die, but its obituary will be written in contract law, not in health economics. The market did not adopt it because it was accurate. The market will not abandon it because it is wrong.
